Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 895 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR EMA Recommends Extension of Indications for Durvalumab July 27, 2020 FDA Proposes Rule Prohibiting Menthol Cigarettes June 27, 2022 Research with integrity – all the fun of the FAIR August 8, 2023 Seven Ways an Occupational Therapist Can Help Patients Recovering From Breast... April 30, 2021 Load more HOT NEWS Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers German Shepherds Detect Fast-Growing Form Of Breast Cancer And Save Their... Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer? Can we grow the treatments of tomorrow? – That Cancer Conversation
